Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2014 - 2026)
Rocket Pharmaceuticals (RCKT) reported Income from Continuing Operations of 48823000.0 for Q1 2026, up 23.14% on a YoY basis from 39647583.92 in Q1 2025, and down 11.61% sequentially from 43746000.0 in Q4 2025.
Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals (RCKT) has 13 years of Income from Continuing Operations data on file, last reported at 48823000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 23.14% year-over-year to 48823000.0; the trailing twelve-month figure through Mar 2026 stood at 310003000.0 (down 16.75% YoY), and the FY2025 full-year result was 361614000.0, up 8.22% from the prior year.
- Income from Continuing Operations declined to 48823000.0 in Q1 2026, from 43746000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 43746000.0 in Q4 2025 to a low of 190825000.0 in Q3 2023.
- A 5-year average of 100417235.29 and a median of 71889000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 67.35% in 2022 and sank 64.86% in 2025, its largest moves.
- Tracing RCKT's Income from Continuing Operations over 5 years: stood at 68304000.0 in 2022, then grew by 7.86% to 62935000.0 in 2023, then grew by 2.2% to 61550000.0 in 2024, then grew by 28.93% to 43746000.0 in 2025, then decreased by 11.61% to 48823000.0 in 2026.
- Business Quant data shows RCKT's Income from Continuing Operations at 48823000.0 in Q1 2026, 43746000.0 in Q4 2025, and 98921000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Rocket Pharmaceuticals | 357.93 Mn | 357.93 Mn | - | -48.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.82 Mn |
| Dec 31, 2025 | -43.75 Mn |
| Sep 30, 2025 | -98.92 Mn |
| Jun 30, 2025 | -118.51 Mn |
| Mar 31, 2025 | -63.52 Mn |
| Dec 31, 2024 | -61.55 Mn |
| Sep 30, 2024 | -68.57 Mn |
| Jun 30, 2024 | -71.89 Mn |
| Mar 31, 2024 | -64.82 Mn |
| Dec 31, 2023 | -62.94 Mn |
| Sep 30, 2023 | -190.83 Mn |
| Jun 30, 2023 | -188.38 Mn |
| Mar 31, 2023 | -157.55 Mn |
| Dec 31, 2022 | -68.30 Mn |
| Sep 30, 2022 | -145.59 Mn |
| Jun 30, 2022 | -126.26 Mn |
| Mar 31, 2022 | -126.90 Mn |
| Dec 31, 2021 | -43.95 Mn |
| Sep 30, 2021 | -252.62 Mn |
| Jun 30, 2021 | -380.53 Mn |